Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NRF2 activator-treated human cardiac spheres have enhanced maturation and enable disease modeling

ABSTRACT: NRF2 activator-treated human cardiac spheres have enhanced maturation and enable disease modeling

PROVIDER: PRJNA846342 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19552231_1.fastq.gz	Fastqsanger.gz
	SRR19552231_2.fastq.gz	Fastqsanger.gz
	SRR19552232_1.fastq.gz	Fastqsanger.gz
	SRR19552232_2.fastq.gz	Fastqsanger.gz
	SRR19552233_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

NRF2 activator-treated human cardiac spheres have enhanced maturation and enable disease modeling

Project description:To investigate the functions of NRF2 activation on maturation of hiPSC derived cardiomyocytes, we treated 3D hiPSC derived cardiomyocytes with NRF2 activator CDDO-Me at 0.5 µM for 10 days. Transcriptomic analyse was performed to identify molecular actions of NRF2 activation.

2022-06-08 | GSE205566 | GEO

AMPK activator-treated human cardiac spheres have enhanced maturation and enable pathological modeling

Project description:AMPK activator-treated human cardiac spheres have enhanced maturation and enable pathological modeling

| PRJNA840926 | ENA

AMPK activator-treated human cardiac spheres have enhanced maturation and enable pathological modeling

Project description:To investigate the functions of AMPK activation on maturation of hiPSC derived cardiomyocytes, we treated 3D hiPSC derived cardiomyocytes with AMPK activator EX229 at 10 µM for 7 days. Transcriptomic analyse was performed to identify molecular actions of AMPK activation.

2022-05-27 | GSE203480 | GEO

Novel KEAP1 activator targeting C151 enhances CUL3 binding and decreases NRF2

Project description:Novel KEAP1 activator targeting C151 enhances CUL3 binding and decreases NRF2

2025-12-10 | PXD056257 | Pride

AMPK activator-treated human cardiac spheres enhance maturation and enable pathological modeling.

Project description:BackgroundCardiac pathological outcome of metabolic remodeling is difficult to model using cardiomyocytes derived from human-induced pluripotent stem cells (hiPSC-CMs) due to low metabolic maturation.MethodshiPSC-CM spheres were treated with AMP-activated protein kinase (AMPK) activators and examined for hiPSC-CM maturation features, molecular changes and the response to pathological stimuli.ResultsTreatment of hiPSC-CMs with AMPK activators increased ATP content, mitochondrial membrane potential and content, mitochondrial DNA, mitochondrial function and fatty acid uptake, indicating increased metabolic maturation. Conversely, the knockdown of AMPK inhibited mitochondrial maturation of hiPSC-CMs. In addition, AMPK activator-treated hiPSC-CMs had improved structural development and functional features-including enhanced Ca2+ transient kinetics and increased contraction. Transcriptomic, proteomic and metabolomic profiling identified differential levels of expression of genes, proteins and metabolites associated with a molecular signature of mature cardiomyocytes in AMPK activator-treated hiPSC-CMs. In response to pathological stimuli, AMPK activator-treated hiPSC-CMs had increased glycolysis, and other pathological outcomes compared to untreated cells.ConclusionAMPK activator-treated cardiac spheres could serve as a valuable model to gain novel insights into cardiac diseases.

| S-EPMC10633979 | biostudies-literature

Modeling NRF2-Driven Anti-inflammatory, Tumor-promoting Macrophages In Vitro

Project description:Modeling NRF2-Driven Anti-inflammatory, Tumor-promoting Macrophages In Vitro

| PRJNA1228020 | ENA

Endothelial cell Nrf2 controls neuroinflammation following a systemic insult

Project description:Systemic inflammation can lead to neuroinflammation with acute consequences such as delirium and long-lasting deleterious effects including cognitive decline and the exacerbation of neurodegenerative disease progression. Here we show that transcription factor Nrf2 controls brain endothelial cell homeostasis and barrier strength. We found that peripheral inflammation caused infiltration of macrophages, microglial activation and inflammatory reactive astrogliosis, all of which could be prevented by RTA-404, an activator of the transcription factor Nrf2 and close structural relative of the recently FDA-approved Nrf2 activator RTA-408 (Omaveloxolone). To identify the key cellular mediator(s), we generated an endothelial cell-specific Nrf2 knockout mouse. Strikingly, the effects of RTA-404 on brain endothelial activation and downstream neuroinflammatory events were abolished by endothelial cell-specific Nrf2 deletion. This places endothelial cell Nrf2 as a peripherally accessible therapeutic target to reduce the CNS-adverse consequences of systemic inflammation

2025-05-02 | PXD063497 | Pride

Effects of Oltipraz on Gene Expression in the Livers of Wild-Type and Nrf2-null Mice

Project description:Oltipraz is an activator of Nrf2 but is also an activator of other pathways including those mediated by constitutive activated receptor (CAR). To identify genes regulated by oltipraz that were Nrf2-dependent, we compared gene expression after exposure in wild-type and Nrf2-null mice. Wild-type or Nrf2-null mice were treated each day for 4 days with 75 mg/kg/day/day oltipraz in corn oil or corn oil alone. There were 4 biological replicates used for each of the 4 genotype-treatment groups. Gene expression in the livers of the mice was evaluated using Affymetrix mouse exon arrays (MoEx-1_0-st-v1).

2016-08-16 | E-GEOD-85222 | biostudies-arrayexpress

Nrf2 transcript alterations

Project description:WGS and RNA-seq data for Nrf2 study

| EGAS00001001740 | EGA

Modeling NRF2-Driven Anti-inflammatory, Tumor-promoting Macrophages In Vitro II

Project description:Modeling NRF2-Driven Anti-inflammatory, Tumor-promoting Macrophages In Vitro II

| PRJNA1228019 | ENA